Number of participants who received at least one dose of ceftazidime-avibactam according to type of use as monotherapy or combination therapy was reported in this outcome measure. Index date was start date of ceftazidime-avibactam.

FAS72+ population included all participants with at least 72 hours of exposure to ceftazidime-avibactam.

Number of participants who received at least one dose of ceftazidime-avibactam according to type of use as monotherapy or combination therapy was reported in this outcome measure.

FAS72- population included all participants with < 72 hours exposure to ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

The total cumulative dose and daily dose of ceftazidime-avibactam was reported in this outcome measure. Total cumulative dose was defined as the sum of all doses received.

FAS72+ population included all participants with at least 72 hours of exposure to ceftazidime-avibactam.

The total cumulative dose and daily dose of ceftazidime-avibactam was reported in this outcome measure. Total cumulative dose was defined as the sum of all doses received.

FAS72- population included all participants with < 72 hours exposure to ceftazidime-avibactam.

Number of participants classified according to frequency of dose (once daily [OD], every other day [QOD], post-dialysis, each 48 hours [h], three times daily [TID], twice daily [BD], four times daily [QID], once loading dose [an initial higher dose of a drug that may be given at the beginning of a course of treatment before dropping down to a lower maintenance dose], every three days, once, etc.,) for ceftazidime-avibactam were reported in this outcome measure.

FAS72+ population included all participants with at least 72 hours of exposure to ceftazidime-avibactam.

Number of participants classified according to frequency of dose (once daily [OD], every other day [QOD], each 48 hours [h], continuous infusion per 48 hours [c/48 h], three times daily [TID], twice daily [BD], four times daily [QID], one dose, loading dose [an initial higher dose of a drug that may be given at the beginning of a course of treatment before dropping down to a lower maintenance dose] etc.,) for ceftazidime-avibactam were reported in this outcome measure.

FAS72- population included all participants with < 72 hours exposure to ceftazidime-avibactam.

Total duration of administration was calculated as stop date of administration of ceftazidime-avibactam minus start date of ceftazidime-avibactam administration plus 1.

FAS72+ population included all participants with at least 72 hours of exposure to ceftazidime-avibactam.

Total duration of administration was calculated as stop date of administration of ceftazidime-avibactam minus start date of ceftazidime-avibactam administration plus 1.

FAS72- population included all participants with < 72 hours exposure to ceftazidime-avibactam.

Number of participants according to the reasons for discontinuation of ceftazidime-avibactam were reported in this outcome measure.

FAS72+ population included all participants with at least 72 hours of exposure to ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

Number of participants according to the reasons for discontinuation of ceftazidime-avibactam were reported in this outcome measure.

FAS72- population included all participants with < 72 hours exposure to ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

The number of participants classified according to antibiotics used concurrently with ceftazidime-avibactam were reported in this outcome measure. Participants could have received more than 1 antibiotic.

FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam.

The number of participants classified according to reason for initiating specific antibiotics combined with ceftazidime-avibactam were reported in this outcome measure. One participant could have received more than 1 antibiotics and there could be more than 1 reason for initiating antibiotics.

FAS72+ population included all participants with at least 72 hours of exposure to ceftazidime-avibactam. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.

The number of participants classified according to reason for discontinuing specific antibiotics combined with ceftazidime-avibactam were reported in this outcome measure. One participant could have received more than 1 antibiotics and there could be more than 1 reason for discontinuing antibiotics.

FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam. Here, "Number Analyzed" signifies number of participants evaluable for the specified rows.

The number of participants whose samples were taken for clinical microbiological evaluation after end of ceftazidime-avibactam therapy were reported in this outcome measure.

MOD population included all participants with at least 72 hours exposure to ceftazidime-avibactam, identification of one or more pathogens before the start of ceftazidime-avibactam treatment, and at least one non-missing microbiological outcome. Not all participants of MOD population had data collected after end of ceftazidime-avibactam therapy. Hence, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

The number of participants classified according to the type of specimen taken for clinical microbiological evaluation after end of ceftazidime-avibactam therapy were reported in this outcome measure. More than 1 type of specimen could have been taken from 1 participant.

MOD population included all participants with at least 72 hours exposure to ceftazidime-avibactam, identification of one or more pathogens before the start of ceftazidime-avibactam treatment, and at least one non-missing microbiological outcome. Not all participants of MOD population had data collected after end of ceftazidime-avibactam therapy. Hence, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

The number of participants classified according to the pathogens identified from the microbiological culture after treatment initiation were reported in this outcome measure.

MOD population included all participants with at least 72 hours exposure to ceftazidime-avibactam, identification of one or more pathogens before the start of ceftazidime-avibactam treatment, and at least one non-missing microbiological outcome. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

The number of gram-negative pathogens according to the susceptibility to specific antibiotics after treatment initiation were reported in this outcome measure.

FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

Multi-drug resistance was defined as the isolate being non-susceptible to at least one agent in more than or equal to (>=) 3 antimicrobial categories, excluding the therapeutic classes to which the pathogen was intrinsically resistant. The number of gram-negative pathogens classified according to the antibiotic resistance to specified antibiotics after treatment initiation were reported in this outcome measure.

FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

The number of participants classified according to type of clinical evaluation outcome as success, failure or indeterminate. Success: resolution of all signs and symptoms of infection with no need for escalation of antimicrobials for gram-negative coverage. Failure: inadequate response to ceftazidime-avibactam therapy or resistant, worsening, or new recurrent signs and symptoms at the end of ceftazidime-avibactam therapy. Indeterminate: there was not enough information to conclude whether the antibiotic regimen containing ceftazidime-avibactam was a clinical failure or a success.

COD population included all participants with at least 72 hours exposure to ceftazidime-avibactam and at least one non-missing clinical outcome.

The number of participants classified according to type of clinical evaluation outcome as success, failure or indeterminate. Success: resolution of all signs and symptoms of infection with no need for escalation of antimicrobials for gram-negative coverage. Failure: inadequate response to ceftazidime-avibactam therapy or resistant, worsening, or new recurrent signs and symptoms at the end of ceftazidime-avibactam therapy. Indeterminate: there was not enough information to conclude whether the antibiotic regimen containing ceftazidime-avibactam was a clinical failure or a success.

COD population included all participants with at least 72 hours exposure to ceftazidime-avibactam and at least one non-missing clinical outcome. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

The number of participants classified according to type of clinical evaluation outcome as success, failure or indeterminate. Success: resolution of all signs and symptoms of infection with no need for escalation of antimicrobials for gram-negative coverage. Failure: inadequate response to ceftazidime-avibactam therapy or resistant, worsening, or new recurrent signs and symptoms at the end of ceftazidime-avibactam therapy. Indeterminate: there was not enough information to conclude whether the antibiotic regimen containing ceftazidime-avibactam was a clinical failure or a success.

COD population included all participants with at least 72 hours exposure to ceftazidime-avibactam and at least one non-missing clinical outcome. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

The number of participants with microbiological treatment outcome as success were reported in this outcome measure. Success was defined as: absence of causative pathogen from appropriately obtained specimens at the site of infection.

Planned analysis of this outcome measure was cancelled on approval of Scientific Steering Committee as few participants had microbiological cultures after the start of ceftazidime-avibactam.

The number of participants classified according to antibiotics used (Yes or No) for current infection before ceftazidime-avibactam were reported in this outcome measure.

FAS72+ population included all participants with at least 72 hours of exposure to ceftazidime-avibactam.

The number of participants classified according to reason for discontinuing for prior antibiotic therapy were reported in this outcome measure. One participant could have more than 1 reason of discontinuation for prior antibiotic therapy.

FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

In hospital-mortality was defined as deaths occurring after treatment initiation but before hospital discharge. The percentage of participants who died during index hospitalization were reported in this outcome measure.

FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam.

30-day mortality was defined as deaths occurred from index treatment up to within 30 days after hospital discharge including in-hospital mortality.

FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam.

60-day mortality was defined as deaths occurred from index treatment up to within 60 days after hospital discharge including in-hospital mortality.

FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam.

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with the study treatment. AE included both SAEs and non-SAEs. SAE was defined as any untoward medical occurrence at any dose that: resulted in death, was life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required hospitalization or prolongation of existing hospitalization. Only AEs and SAEs with explicit attribution to ceftazidime-avibactam that appeared in the reviewed information and scenarios involving drug exposure to ceftazidime-avibactam, which included exposure during pregnancy, exposure during breastfeeding, medication error, overdose, misuse, extravasation, lack of efficacy and occupational exposure associated with the use of ceftazidime-avibactam were collected in the study.

FAS population included all enrolled participants meeting the study eligibility criteria.

Hospital length of stay (LOS) was defined as date of hospital discharge minus date of hospital admission plus 1. The duration of hospital stay of participants were reported in this outcome measure.

FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

Duration of ICU stay was defined as date of ICU discharge minus date of ICU admission plus 1. The total duration of ICU stay of participants were reported in this outcome measure.

FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

The number of participants readmitted to the hospital during the 30 days after initial discharge were reported in this outcome measure.

FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam.

The number of participants readmitted to the hospital during the 60 days after initial discharge were reported in this outcome measure.

FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam.

The number of participants classified according to the reason for readmission to the hospital were reported in this outcome measure. One participant could have more than 1 reason for readmission to the hospital.

FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

The number of participants classified according to the healthcare resource utilization during the hospitalization were reported in this outcome measure. One participant could have utilized more than 1 healthcare resource during hospitalization.

FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam.

The number of participants classified according to all wards attended during hospitalization were reported in this outcome measure.

FAS72+ population included all participants with at least 72 hours of exposure to Ceftazidime-avibactam. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.